drugset / Trial / NCT04468997
The Study of Drug 601 in Patients With Wet Age-related Macular Degeneration (wAMD)
Non-randomizedSequentialOpen-labelTreatment
Summary
Multicenter study to evaluate the safety and tolerability in patients with wet Age-related macular degeneration (wAMD) treated with intravitreal recombinant humanized anti-VEGF monoclonal antibody
Timeline
- Start
- 2018-11-12
- Primary completion
- 2021-03-15
- Completion
- 2021-09-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Drug 601 | Monoclonal antibody | 0.375 mg | Other |
| Subject | Drug 601 | Monoclonal antibody | 0.75 mg | Other |
| Subject | Drug 601 | Monoclonal antibody | 1.25 mg | Other |
| Subject | Drug 601 | Monoclonal antibody | 2.5 mg | Other |